Board Change • May 15
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Stephanie Phillips was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • Mar 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.6m free cash flow). Earnings have declined by 6.3% per year over the past 5 years. Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (AU$6.1m revenue, or US$4.3m). Market cap is less than US$100m (AU$23.5m market cap, or US$16.5m). Reported Earnings • Mar 03
First half 2026 earnings released: AU$0.011 loss per share (vs AU$0.014 loss in 1H 2025) First half 2026 results: AU$0.011 loss per share. Revenue: AU$2.82m (down 2.6% from 1H 2025). Net loss: AU$3.61m (loss widened 12% from 1H 2025). New Risk • Feb 27
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$4.6m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.6m free cash flow). Earnings have declined by 6.3% per year over the past 5 years. Shareholders have been substantially diluted in the past year (37% increase in shares outstanding). Minor Risks Revenue is less than US$5m (AU$6.0m revenue, or US$4.3m). Market cap is less than US$100m (AU$22.6m market cap, or US$16.1m). Tillkännagivande • Feb 25
Control Bionics Limited to Report First Half, 2026 Results on Feb 26, 2026 Control Bionics Limited announced that they will report first half, 2026 results on Feb 26, 2026 Board Change • Jan 01
High number of new directors Non Executive Chairman Stephen Rix was the last director to join the board, commencing their role in 2025. Tillkännagivande • Dec 01
Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 3.25 million. Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 3.25 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 50,000,000
Price\Range: AUD 0.065
Transaction Features: Subsequent Direct Listing New Risk • Nov 11
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings have declined by 13% per year over the past 5 years. Shareholders have been substantially diluted in the past year (36% increase in shares outstanding). Minor Risks Revenue is less than US$5m (AU$6.1m revenue, or US$4.0m). Market cap is less than US$100m (AU$24.9m market cap, or US$16.2m). Tillkännagivande • Oct 23
Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.062278 million. Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.062278 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 8,852,473
Price\Range: AUD 0.035
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 32,874,567
Price\Range: AUD 0.035
Discount Per Security: AUD 0.00175
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 17,195,180
Price\Range: AUD 0.035
Discount Per Security: AUD 0.0021
Transaction Features: Rights Offering Tillkännagivande • Oct 21
Control Bionics Limited, Annual General Meeting, Nov 25, 2025 Control Bionics Limited, Annual General Meeting, Nov 25, 2025. Location: at level 11, 66 clarence street, nsw., sydney Australia Tillkännagivande • Sep 17
Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.309837 million. Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.309837 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 8,852,473
Price\Range: AUD 0.035
Discount Per Security: AUD 0.00175
Transaction Features: Rights Offering Reported Earnings • Aug 31
Full year 2025 earnings released: AU$0.023 loss per share (vs AU$0.037 loss in FY 2024) Full year 2025 results: AU$0.023 loss per share. Revenue: AU$7.04m (up 32% from FY 2024). Net loss: AU$6.11m (loss widened 3.3% from FY 2024). Tillkännagivande • Aug 28
Control Bionics Limited has filed a Follow-on Equity Offering in the amount of AUD 2.062278 million. Control Bionics Limited has filed a Follow-on Equity Offering in the amount of AUD 2.062278 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 58,922,220
Price\Range: AUD 0.035
Discount Per Security: AUD 0.00175
Transaction Features: Rights Offering Tillkännagivande • Jul 30
Control Bionics Limited to Report Q4, 2025 Results on Jul 31, 2025 Control Bionics Limited announced that they will report Q4, 2025 results on Jul 31, 2025 New Risk • May 15
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (73% increase in shares outstanding). Market cap is less than US$10m (AU$9.43m market cap, or US$6.06m). Minor Risk Revenue is less than US$5m (AU$5.3m revenue, or US$3.4m). Board Change • Apr 01
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Non Executive Director Damian Lismore is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Tillkännagivande • Mar 26
Control Bionics Limited Announces Board Changes Control Bionics Limited announced the appointment of Dr Stephanie Phillips to its Board of Directors, effective immediately. Dr Phillips brings with her over three decades of clinical, academic and leadership experience in anaesthesia and critical care, and is a highly respected figure in the Australian medical community. Dr Phillips (BMed, FRCA, FANZCA, GAICD) is a Consultant Anaesthetist and Clinical Associate Professor at the Australian National University. She has formerly held senior leadership positions at the University of Sydney including Deputy Head of School, and Academic Lead for Education at the Sydney Adventist Hospital Clinical School and was a member of the Academic Boards of both the University and of the Faculty of Medicine. She has been Managing Director of Northern Specialist Anaesthetics Pty Ltd. She was also the Inaugural Chair of the Australian Society of Anaesthetists Science, Prizes, Awards, and Research Committee. Her international training and clinical expertise span paediatric, cardiothoracic and neurosurgical anaesthesia. Her more recent research interests focus on neuromuscular function monitoring during anaesthesia. A veteran of over 10 international medical aid missions, Dr Phillips is deeply committed to improving patient outcomes and reducing anaesthesia-related morbidity. Her strong research background, medical insight and leadership experience will add significant value to Control Bionics as it expands into new markets across assistive communication, rehabilitation and health diagnostics. The Board also announced the resignation of Peter Ford, founder of Control Bionics, from the Board from 31 March 2025. Peter's vision and passion were the driving force behind the creation of Control Bionics. Inspired by a desire to help unlock the potential of brilliant minds like Stephen Hawking, Peter's insight in 1999--that damaged muscles still emit usable electrical signals--led to the development of the NeuroNode and the founding of the Company. Under Peter's guidance, Control Bionics has grown from a visionary idea into a publicly listed company helping people around the world regain their voice and mobility. His legacy is embedded in the DNA of the company, and his impact on the assistive technology sector is profound. While Peter is stepping down from the Board, he remains passionately committed to the success of Control Bionics and continues to be a significant shareholder. New Risk • Mar 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (48% increase in shares outstanding). Market cap is less than US$10m (AU$9.32m market cap, or US$5.88m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (AU$5.3m revenue, or US$3.3m). Tillkännagivande • Feb 26
Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.918088 million. Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.918088 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 42,624,175
Price\Range: AUD 0.045
Transaction Features: Subsequent Direct Listing Tillkännagivande • Feb 25
Control Bionics Limited has filed a Follow-on Equity Offering in the amount of AUD 1.918088 million. Control Bionics Limited has filed a Follow-on Equity Offering in the amount of AUD 1.918088 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 42,624,175
Price\Range: AUD 0.045
Transaction Features: Subsequent Direct Listing Tillkännagivande • Dec 20
Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.895654 million. Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.895654 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 9,938,489
Price\Range: AUD 0.07
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 12,714,286
Price\Range: AUD 0.07
Discount Per Security: AUD 0.0035
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 4,428,000
Price\Range: AUD 0.07
Transaction Features: Rights Offering Board Change • Dec 18
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Independent Non Executive Director Damian Lismore is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Oct 22
Control Bionics Limited Appoints Dr. Samuel Straface (Ph.D.) as New Independent Non-Executive Director Control Bionics Limited appointed Dr. Samuel Straface (Ph.D.) as a new independent non-executive director. Sam is an accomplished Neurophysiologist and has held Senior Executive roles in both Australia and the USA including as President/CEO of multiple Medtech businesses. Sam has extensive experience in the development and commercialisation of premium medical devices and services and will complement the skills of the existing Board in delivering NeuroStrip and other new products to the global market. Tillkännagivande • Sep 25
Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.15 million. Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.15 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 16,428,571
Price\Range: AUD 0.07
Discount Per Security: AUD 0.0042
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing New Risk • Sep 24
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$14.2m (US$9.74m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (104% increase in shares outstanding). Market cap is less than US$10m (AU$14.2m market cap, or US$9.74m). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (AU$5.4m revenue, or US$3.7m). Tillkännagivande • Sep 09
Control Bionics Limited, Annual General Meeting, Oct 10, 2024 Control Bionics Limited, Annual General Meeting, Oct 10, 2024. Location: level 11, 66 clarence street, sydney, nsw Australia Reported Earnings • Aug 28
Full year 2024 earnings released: AU$0.037 loss per share (vs AU$0.062 loss in FY 2023) Full year 2024 results: AU$0.037 loss per share. Revenue: AU$6.36m (up 13% from FY 2023). Net loss: AU$5.91m (loss widened 5.0% from FY 2023). New Risk • Aug 22
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 21% per year over the past 5 years. Shareholders have been substantially diluted in the past year (104% increase in shares outstanding). Minor Risks Revenue is less than US$5m (AU$5.7m revenue, or US$3.8m). Market cap is less than US$100m (AU$19.9m market cap, or US$13.4m). Tillkännagivande • Aug 21
Control Bionics Limited Announces New US Insurance Code Approved Control Bionics Limited announced the Centers for Medicare & Medicaid Services (CMS) has approved a new Healthcare Common Procedure Coding System (HCPCS) code for the NeuroNode®. This means it now qualifies for a US$4300 reimbursement that wasn't previously available. Highlights: Once this becomes effective on 1 October 2024: It results in a material benefit to the business' operations in the US. Represents a substantial opportunity to build a wholesale distribution model for the US - as part of previously explained `NeuroNode® Only' strategy. Control Bionics and any of its existing US partners can from 1 October 2024 apply for the extra ~USD 4,300 reimbursement for customers covered by Medicare and Medicaid and further seek to have this covered `in-network' with private insurers. This approval marks a significant milestone in enhancing the accessibility and insurance coverage of NeuroNode® for users with impaired speech and motor function in the United States. Tillkännagivande • May 18
Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.251526 million. Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.251526 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 29,105,246
Price\Range: AUD 0.043
Discount Per Security: AUD 0.00258
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Tillkännagivande • Jan 19
Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.697642 million. Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.697642 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 15,515,253
Price\Range: AUD 0.04
Discount Per Security: AUD 0.002
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 26,925,800
Price\Range: AUD 0.04
Discount Per Security: AUD 0.002
Transaction Features: Rights Offering New Risk • Dec 06
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 27% per year over the past 5 years. Market cap is less than US$10m (AU$4.83m market cap, or US$3.17m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$1.3m net loss in 3 years). Shareholders have been diluted in the past year (30% increase in shares outstanding). Revenue is less than US$5m (AU$5.6m revenue, or US$3.7m). New Risk • Oct 17
New major risk - Revenue and earnings growth Earnings have declined by 27% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.0m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 27% per year over the past 5 years. Market cap is less than US$10m (AU$6.35m market cap, or US$4.05m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$1.3m net loss in 3 years). Shareholders have been diluted in the past year (13% increase in shares outstanding). Revenue is less than US$5m (AU$5.6m revenue, or US$3.6m). Tillkännagivande • Sep 06
Control Bionics Limited, Annual General Meeting, Oct 10, 2023 Control Bionics Limited, Annual General Meeting, Oct 10, 2023, at 10:30 AUS Eastern Standard Time. Location: University of NSW CBD Campus, Level 7 1, O'Connell St, Sydney, NSW Sydney Australia Agenda: To receive and consider the Company's financial statements and the reports of the Directors and of the Auditor for the year ended 30 June 2023; to consider Remuneration Report; to Re-elect Roger Hawke as a Director; to Re-elect Professor Robert Heard as a Director; to consider Approval of Issue of Options to Managing Director; and to consider other business matters. Reported Earnings • Sep 01
Full year 2023 earnings: EPS and revenues exceed analyst expectations Full year 2023 results: AU$0.062 loss per share (improved from AU$0.072 loss in FY 2022). Revenue: AU$6.11m (up 27% from FY 2022). Net loss: AU$5.63m (loss narrowed 7.7% from FY 2022). Revenue exceeded analyst estimates by 5.9%. Earnings per share (EPS) also surpassed analyst estimates by 4.0%. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. New Risk • Aug 26
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.1m free cash flow). Earnings have declined by 32% per year over the past 5 years. Market cap is less than US$10m (AU$7.89m market cap, or US$5.06m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (13% increase in shares outstanding). Revenue is less than US$5m (AU$5.3m revenue, or US$3.4m). New Risk • Aug 02
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 13% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.1m free cash flow). Earnings have declined by 32% per year over the past 5 years. Market cap is less than US$10m (AU$7.68m market cap, or US$5.06m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$2.2m net loss in 2 years). Shareholders have been diluted in the past year (13% increase in shares outstanding). Revenue is less than US$5m (AU$5.3m revenue, or US$3.5m). Tillkännagivande • Jun 14
Control Bionics Limited Provides Revenue Guidance for the Year Ended 30 June 2023 Control Bionics Limited provided revenue guidance for the year ended 30 June 2023. The revenue for the year ended 30 June 2023 is expected to be approximately $5.3 million, a more than 20% increase in the revenue of $4.4 million for the year ended 30 June 2022. Tillkännagivande • May 05
Control Bionics Limited Announces Directorate Changes The Board of Control Bionics Limited welcomed Professor Robert Heard as a new independent non-executive director. Robert is a distinguished medical practitioner and Professor of Neurology who brings a wealth of relevant knowledge and experience to its Board. Professor Heard replaces Lindsay Phillips, a long-term director of the Company, who is retiring in order to diversify the skill set of the Board and to achieve its goal of having a majority of independent directors. Reported Earnings • Feb 24
First half 2023 earnings released: AU$0.033 loss per share (vs AU$0.037 loss in 1H 2022) First half 2023 results: AU$0.033 loss per share (improved from AU$0.037 loss in 1H 2022). Revenue: AU$2.98m (up 22% from 1H 2022). Net loss: AU$3.00m (loss narrowed 4.1% from 1H 2022). Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Medical Equipment industry in Australia. Price Target Changed • Feb 23
Price target decreased by 32% to AU$0.58 Down from AU$0.85, the current price target is provided by 1 analyst. New target price is 262% above last closing price of AU$0.16. Stock is down 54% over the past year. The company posted a net loss per share of AU$0.072 last year. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Non Executive Director Damian Lismore was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Sep 15
Control Bionics Limited Announces Resignation of Rob Wong as CEO Control Bionics Limited announced the resignation of company's CEO, Rob Wong, due to an ongoing, degenerative medical condition. Rob has been on sick leave for the last 2 months seeking treatment and taking time to recover, during which time Company's Founder, Peter Ford, has stepped into the CEO role on a temporary basis. Rob has now concluded that he will be unable to perform the demanding role of CEO, and instead must focus his energy on his health and his family. The Board has commenced a search process for a new permanent CEO. Rob Wong remains a significant shareholder and is making himself available in an advisory capacity as needed, and will assist with the transition to a new CEO at the appropriate time. Tillkännagivande • Aug 25
Control Bionics Limited, Annual General Meeting, Oct 06, 2022 Control Bionics Limited, Annual General Meeting, Oct 06, 2022, at 11:01 AUS Eastern Standard Time. Location: at Level 3, 22 Market Street Sydney New South Wales Australia Agenda: To consider Remuneration Report; to Re-elect Lindsay Phillips as a Director; to consider Additional Share Issue Capacity under Listing Rule 7.1A; to consider Amendment to Constitution; to consider other matters, if any. Reported Earnings • Aug 25
Full year 2022 earnings released: AU$0.071 loss per share (vs AU$0.057 loss in FY 2021) Full year 2022 results: AU$0.071 loss per share (down from AU$0.057 loss in FY 2021). Revenue: AU$4.90m (up 20% from FY 2021). Net loss: AU$6.10m (loss widened 72% from FY 2021). Over the next year, revenue is forecast to grow 41%, compared to a 17% growth forecast for the Medical Equipment industry in Australia. Price Target Changed • Jul 29
Price target decreased to AU$0.89 Down from AU$1.32, the current price target is provided by 1 analyst. New target price is 287% above last closing price of AU$0.23. Stock is down 65% over the past year. The company is forecast to post a net loss per share of AU$0.064 next year compared to a net loss per share of AU$0.057 last year. Recent Insider Transactions Derivative • Jul 26
Founder exercised options to buy AU$821k worth of stock. On the 25th of July, Peter Ford exercised options to buy 4m shares at a strike price of around AU$0.21, costing a total of AU$749k. This transaction amounted to 17% of their direct individual holding at the time of the trade. Since September 2021, Peter has owned 21.26m shares directly. Company insiders have collectively bought AU$1.5m more than they sold, via options and on-market transactions, in the last 12 months. Tillkännagivande • Jul 19
Control Bionics Limited Appoints Dominik Kucera as Its Chief Financial Officer on an Interim Basis Control Bionics Limited (CBL) has engaged Dominik Kucera as its chief financial officer on an interim basis. CBL is continuing to search for a CFO to be appointed on a permanent basis. Dominik is a highly experienced chief financial officer, having previously served as CFO for a number of private and ASX listed companies. Tillkännagivande • Jun 10
Control Bionics Limited Announces Resignation of CFO Control Bionics Limited advises that its chief financial officer, Neale Java, has resigned. Neale joined CBL just after the Company's IPO and provided significant guidance as a newly listed company. The Management and Board of CBL acknowledge Neale's contribution to CBL and wish Neale success in his future endeavours. Pitcher Partners, who currently provide CBL accounting services, have been engaged to provide CFO services, until a new CFO can be appointed. This announcement was authorised by CBL CEO, Rob Wong. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Non Executive Director Damian Lismore was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 24
First half 2022 earnings: EPS in line with analyst expectations despite revenue beat First half 2022 results: AU$0.037 loss per share. Revenue: AU$2.45m (flat on 1H 2021). Net loss: AU$3.13m (flat on 1H 2021). Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 63%, compared to a 16% growth forecast for the industry in Australia. Major Estimate Revision • Jan 29
Consensus revenue estimates fall by 13% The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from AU$6.88m to AU$5.96m. Forecast losses increased from -AU$0.04 to -AU$0.07 per share. Medical Equipment industry in Australia expected to see average net income decline 16% next year. Consensus price target down from AU$1.42 to AU$1.32. Share price fell 3.8% to AU$0.39 over the past week. Price Target Changed • Jan 28
Price target decreased to AU$1.32 Down from AU$1.42, the current price target is provided by 1 analyst. New target price is 243% above last closing price of AU$0.39. Stock is down 54% over the past year. The company is forecast to post a net loss per share of AU$0.041 next year compared to a net loss per share of AU$0.057 last year. Recent Insider Transactions Derivative • Dec 26
CEO & Board Member exercised options to buy AU$1.4m worth of stock. On the 23rd of December, Robert Wong exercised options to buy 3m shares at a strike price of around AU$0.21, costing a total of AU$707k. This transaction amounted to 132% of their direct individual holding at the time of the trade. Since June 2021, Robert has owned 2.54m shares directly. Company insiders have collectively bought AU$769k more than they sold, via options and on-market transactions, in the last 12 months. Reported Earnings • Aug 27
Full year 2021 earnings released The company reported a mediocre full year result with increased losses and weaker control over costs, although revenues improved. Full year 2021 results: Revenue: AU$4.43m (up 38% from FY 2020). Net loss: AU$3.55m (loss widened 253% from FY 2020). Is New 90 Day High Low • Mar 12
New 90-day low: AU$0.62 The company is down 38% from its price of AU$1.00 on 11 December 2020. The Australian market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 5.0% over the same period. Tillkännagivande • Feb 23
Control Bionics Limited to Report First Half, 2021 Results on Feb 25, 2021 Control Bionics Limited announced that they will report first half, 2021 results on Feb 25, 2021 Tillkännagivande • Feb 08
Control Bionics Limited Announces Executive Changes Control Bionics Limited announces the appointment of Neale Java as Chief Financial Officer (CFO). The appointment of Neale is part of a planned transition whereby CBL's current CFO, John Bell, will remain with the company up to 1 April 2021 and will be responsible for completion of the half year accounts ended 31 December 2020. Neale will assume full CFO responsibilities from 1 March 2021. He will also have operational responsibilities for Australia and USA markets. 
